



**Contact:**

Kim Bland, Ph.D.  
Director of Research & Development  
Proteon Therapeutics, LLC  
4420 Madison Ave., Suite 180  
Kansas City, Missouri 64111  
[contact@proteontherapeutics.com](mailto:contact@proteontherapeutics.com)  
(816) 531-0028

MEDIA RELEASE

MEDIA RELEASE

MEDIA RELEASE

MEDIA RELEASE

---

**Proteon Therapeutics, LLC and The University of Kansas Medical Center  
Present at the Annual Meeting of the American Society of Nephrology**

**For Immediate Release**

**KANSAS CITY, Mo (Jan. 3, 2006)** — Proteon Therapeutics, LLC (“Proteon”) and the University of Kansas Medical Center (“KUMC”) made an oral presentation at the 38<sup>th</sup> annual meeting of the American Society of Nephrology on Nov. 10, 2005 in Philadelphia, Pa. Nationally, this event is the leading venue for announcing breakthroughs in renal care.

Kirk A. Hance, M.D. presented pre-clinical data demonstrating the effect of treating hemodialysis access sites with PRT-201, Proteon’s lead drug candidate. On average, PRT-201 treatment dilated the outflow vein of hemodialysis access sites by 44% and reduced site failure by 67%. Dr. Hance performed the work while on the faculty of KUMC.

F. Nicholas Franano, M.D., M.A. and CEO of Proteon stated, “Dr. Hance’s work adds independent validation that is consistent with previous studies. In total, PRT-201 has demonstrated robust efficacy in more than 20 pre-clinical trials and multiple animal models. We are now confidently moving forward into manufacturing, pharmacology and toxicology studies, and human clinical trials.”

This project was supported, in part, by a \$158,000 Phase I Small Business Technology Transfer (STTR) grant by the National Institute of Health (NIH) and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The NIH and the Center for Medicare Services have publicly recognized hemodialysis access failure as a critical, unmet medical need.

-more-

### **About Proteon:**

Proteon is a biopharmaceutical company developing PRT-201, a novel human recombinant protein that permanently dilates segments of blood vessels, blocks vasospasm, and reduces the formation of vascular scarring. This unique combination of features is crucial for improving both the immediate and long-term success of hemodialysis access, bypass graft, and angioplasty procedures.

####